CompanyHealthAi
Sensorium Therapeutics
Sensorium Therapeutics is a Boston-based biotechnology company building first-in-class central nervous system (CNS) medicines by decoding nature's neuroactive chemistry with AI. Founded out of Massachusetts General Hospital and Harvard, its proprietary SensAI platform mines more than 50 million curated relationships across ethnopharmacology, chemistry, pharmacology, and clinical outcomes to identify de-risked starting points for new drugs. Its lead program, SNTX-2643, is a rapid-acting precision serotonin modulator for anxiety that received FDA IND clearance in 2025.
2021Founded
BostonHQ
$25MSeries A (extension)
biotechmental healthdrug discoverycns therapeuticsneuroscienceai drug discovery